WallStSmart

Johnson & Johnson (JNJ)vsMP Materials Corp (MP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Johnson & Johnson generates 34095% more annual revenue ($94.19B vs $275.46M). JNJ leads profitability with a 28.5% profit margin vs -31.2%. JNJ earns a higher WallStSmart Score of 71/100 (B).

JNJ

Strong Buy

71

out of 100

Grade: B

Growth: 7.3Profit: 9.0Value: 10.0Quality: 7.0
Piotroski: 4/9Altman Z: 2.62

MP

Avoid

29

out of 100

Grade: F

Growth: 4.7Profit: 2.0Value: 5.0Quality: 7.5
Piotroski: 4/9Altman Z: 1.13
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

JNJUndervalued (+54.5%)

Margin of Safety

+54.5%

Fair Value

$516.67

Current Price

$239.93

$276.74 discount

UndervaluedFair: $516.67Overvalued

Intrinsic value data unavailable for MP.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

JNJ6 strengths · Avg: 8.8/10
Market CapQuality
$567.22B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
35.0%10/10

Every $100 of equity generates 35 in profit

Profit MarginProfitability
28.5%9/10

Keeps 28 of every $100 in revenue as profit

Operating MarginProfitability
24.0%8/10

Strong operational efficiency at 24.0%

EPS GrowthGrowth
48.6%8/10

Earnings expanding 48.6% YoY

Free Cash FlowQuality
$5.47B8/10

Generating 5.5B in free cash flow

MP1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
70.0%10/10

Revenue surging 70.0% year-over-year

Areas to Watch

JNJ1 concerns · Avg: 4.0/10
PEG RatioValuation
1.654/10

Expensive relative to growth rate

MP4 concerns · Avg: 2.0/10
Return on EquityProfitability
-5.0%2/10

ROE of -5.0% — below average capital efficiency

EPS GrowthGrowth
-55.6%2/10

Earnings declined 55.6%

Free Cash FlowQuality
$-109.26M2/10

Negative free cash flow — burning cash

Altman Z-ScoreHealth
1.132/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : JNJ

The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 28.5% and operating margin at 24.0%.

Bull Case : MP

The strongest argument for MP centers on Revenue Growth. Revenue growth of 70.0% demonstrates continued momentum.

Bear Case : JNJ

The primary concerns for JNJ are PEG Ratio.

Bear Case : MP

The primary concerns for MP are Return on Equity, EPS Growth, Free Cash Flow.

Key Dynamics to Monitor

JNJ profiles as a mature stock while MP is a hypergrowth play — different risk/reward profiles.

MP carries more volatility with a beta of 1.62 — expect wider price swings.

MP is growing revenue faster at 70.0% — sustainability is the question.

JNJ generates stronger free cash flow (5.5B), providing more financial flexibility.

Bottom Line

JNJ scores higher overall (71/100 vs 29/100), backed by strong 28.5% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Johnson & Johnson

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.

Visit Website →

MP Materials Corp

BASIC MATERIALS · OTHER INDUSTRIAL METALS & MINING · USA

MP Materials Corp. The company is headquartered in Las Vegas, Nevada.

Want to dig deeper into these stocks?